10,000 Shares in Merck & Co., Inc. $MRK Purchased by CV Advisors LLC

CV Advisors LLC acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $1,285,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in MRK. Kingdom Financial Group LLC. purchased a new stake in Merck & Co., Inc. in the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $26,000. Abound Financial LLC purchased a new position in Merck & Co., Inc. during the fourth quarter valued at $26,000. IFC & Insurance Marketing Inc. bought a new stake in Merck & Co., Inc. in the fourth quarter worth $31,000. Finally, High Note Wealth LLC raised its position in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
• Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
• Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
• Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the transaction, the executive vice president directly owned 46,613 shares in the company, valued at $6,106,303. This represents a 24.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Richard R. Deluca sold 20,784 shares of Merck & Co., Inc. stock in a transaction on Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the sale, the executive vice president owned 134,703 shares in the company, valued at approximately $17,569,312.29. This represents a 13.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 228,238 shares of company stock worth $29,977,783 in the last quarter. 0.17% of the stock is owned by insiders.

Merck & Co., Inc. Stock Up 0.2%

Shares of MRK stock opened at $135.78 on Friday. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $135.97. The stock has a market cap of $334.98 billion, a P/E ratio of 108.62, a P/E/G ratio of 5.85 and a beta of 0.19. The company has a current ratio of 1.32, a quick ratio of 1.06 and a debt-to-equity ratio of 1.22. The company has a 50 day simple moving average of $125.54 and a two-hundred day simple moving average of $119.94.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts expect that Merck & Co., Inc. will post 2.77 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.5%. Merck & Co., Inc.’s payout ratio is 272.00%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Daiwa Securities Group upgraded shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a research note on Wednesday. JPMorgan Chase & Co. upped their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Wells Fargo & Company boosted their price objective on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Finally, BMO Capital Markets boosted their target price on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Fifteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average price target of $135.50.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.